Applied Cell Biology

ISSN : 2320-1991 Online
ISSN : 2320-1983 Print
Volume 13 Issue 3
DOI: https://dx.doi.org/10.53043/2320-1991.acb13013

Short Communication
Appl Cell Biol, 13(3), 2025 [74-77]
Published: August 11, 2025

Immune Cell Crosstalk as a Central Mechanism in Autoimmune and Neuroinflammatory Disease

Liu Yang[1], Wang Yun[2]*

Hunan Engineering Technology Center of Standardization and Function of Chinese Herbal Decoction Pieces, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China

State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica & Neuroscience Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

***Corresponding author:** Wang Yun, State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica & Neuroscience Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

ABSTRACT

Autoimmune and neuroinflammatory diseases arise from complex and sustained disturbances in immune regulation rather than from isolated cellular defects. Increasing evidence indicates that pathological outcomes in these conditions are driven by aberrant communication networks among immune cells operating across peripheral tissues, the central nervous system, and immune–privileged compartments. Immune cell crosstalk governs antigen recognition, cytokine amplification, tissue infiltration, and resolution of inflammation, and its dysregulation leads to chronic immune activation, loss of tolerance, and progressive tissue damage. This short communication synthesizes current understanding of immune cell–cell interactions as a unifying mechanistic framework underlying autoimmune and neuroinflammatory disorders. Emphasis is placed on bidirectional signaling between innate and adaptive immune populations, the role of cytokine and chemokine circuits, and the influence of tissue-specific microenvironments on immune behavior. Practical implications for disease monitoring and therapeutic intervention are discussed, highlighting how targeting immune communication networks rather than single cell types may provide more durable clinical benefit. By integrating mechanistic insights with translational perspectives, this work underscores immune crosstalk as a central determinant of disease initiation, propagation, and therapeutic responsiveness.

Keywords

Immune cell crosstalk
Autoimmunity
Neuroinflammation
Cytokine networks
Immune regulation

SHORT COMMUNICATION

Autoimmune and neuroinflammatory diseases represent a broad spectrum of chronic disorders characterized by immune-mediated tissue injury, persistent inflammation, and progressive functional impairment. Conditions such as multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, neuromyelitis optica, and autoimmune encephalitis share common immunopathological features despite targeting distinct organs and tissues. Traditionally, research efforts have focused on identifying pathogenic immune cell subsets, disease-specific autoantibodies, or dysregulated cytokines. While these approaches have yielded critical insights, they often fail to fully explain disease heterogeneity, fluctuating clinical courses [1], and variable therapeutic responses. Increasingly, it has become clear that disease pathogenesis cannot be attributed to isolated immune components but instead emerges from dysfunctional interactions among immune cells operating within complex biological systems.

Immune cell crosstalk refers to the dynamic exchange of signals between immune cells through direct contact, soluble mediators, extracellular vesicles, and metabolic cues. These interactions are essential for maintaining immune

Short Communication

homeostasis, coordinating protective responses, and resolving inflammation. In autoimmune and neuroinflammatory diseases, however, immune crosstalk becomes maladaptive, reinforcing inflammatory loops and perpetuating immune activation even in the absence of external threats. This conceptual shift—from single-cell pathology to network-level dysregulation—has profound implications for understanding disease mechanisms and designing therapeutic strategies [2].

At the core of immune crosstalk is the coordinated activity of innate and adaptive immune systems. Innate immune cells, including dendritic cells, macrophages, microglia, and neutrophils, serve as primary sensors of tissue damage and danger signals. Through pattern recognition receptors and inflammasome activation, these cells initiate inflammatory responses and shape downstream adaptive immunity. In autoimmune and neuroinflammatory contexts, aberrant activation of innate immune cells leads to excessive antigen presentation [3,4], sustained cytokine release, and altered costimulatory signaling. This creates a permissive environment for the activation and expansion of autoreactive T and B lymphocytes.

Adaptive immune cells, particularly $CD4^+$ T helper subsets, cytotoxic $CD8^+$ T cells [5], regulatory T cells, and antibody-producing B cells, further amplify immune crosstalk through reciprocal signaling. Pathogenic T helper cell subsets, such as Th1 and Th17 cells, release pro-inflammatory cytokines that activate macrophages, endothelial cells, and resident tissue cells. These signals promote immune cell recruitment, vascular permeability, and tissue infiltration, hallmarks of autoimmune and neuroinflammatory pathology. Conversely, defects in regulatory T cell function disrupt inhibitory signaling pathways that normally constrain immune activation, allowing inflammatory circuits to persist unchecked [6].

In neuroinflammatory diseases, immune crosstalk extends beyond traditional immune compartments to involve central nervous system–resident cells. Microglia, astrocytes, and endothelial cells participate actively in immune signaling, responding to peripheral immune cues and shaping local inflammatory responses. The breakdown of the blood–brain barrier, a key event in many neuroinflammatory conditions, exemplifies the consequences of dysregulated immune communication. Cytokines and chemokines released by activated immune cells alter barrier integrity (Figure 1), enabling further immune cell infiltration and establishing a self-reinforcing cycle of inflammation. This schematic illustrates the dynamic and bidirectional communication between innate immune cells (dendritic cells, macrophages, and microglia) and adaptive immune cells (Th1/Th17 cells, $CD8^+$ T cells, B cells, and regulatory T cells) within autoimmune and neuroinflammatory settings. Cytokine release, chemokine



Figure 1: Immune cell crosstalk driving autoimmune and neuroinflammatory disease.

gradients, antigen presentation, and direct cell–cell interactions coordinate immune activation and regulation. These immune signals converge on the central nervous system and tissue microenvironment, where interactions with endothelial cells, astrocytes, and neurons promote immune cell infiltration, sustained neuroinflammation, and progressive tissue damage [7].

Cytokine and chemokine networks form the molecular backbone of immune cell crosstalk. These soluble mediators act as both messengers and amplifiers [8], translating cellular interactions into coordinated tissue-level responses. In autoimmune and neuroinflammatory diseases, cytokine signaling becomes skewed toward pro-inflammatory profiles, with excessive production of interleukins, interferons, and tumor necrosis factors. Importantly, the pathological impact of these molecules depends not only on their concentration but also on the timing, cellular source, and local microenvironment in which they operate. This contextual dependence explains why targeting individual cytokines yields variable clinical outcomes and underscores the importance of understanding immune crosstalk as an integrated system.

Beyond soluble mediators, direct cell–cell contact plays a critical role in immune regulation. Costimulatory and coinhibitory receptor–ligand interactions fine-tune immune responses and determine cell fate decisions. In autoimmune disease, alterations in these signaling axes enhance immune activation and resistance to regulatory mechanisms. Similarly, neuroinflammatory conditions exhibit changes in adhesion molecules and synaptic-like contacts between immune cells and neural cells, facilitating sustained inflammatory signaling within the nervous system [9].

Metabolic interactions further contribute to immune crosstalk by linking cellular function to environmental cues. Immune cells compete for nutrients, respond to metabolic byproducts, and adjust their functional programs accordingly. In inflamed tissues, metabolic reprogramming favors glycolysis and oxidative stress, promoting inflammatory phenotypes and impairing regulatory pathways [10,11]. These metabolic shifts not only affect individual cells but also reshape communication networks across immune populations.

From a practical perspective, recognizing immune cell crosstalk as a central pathogenic mechanism offers new opportunities for diagnosis and treatment. Biomarkers that capture network-level immune activity, rather than single molecules, may provide more accurate indicators of disease activity and therapeutic response. Similarly, interventions that modulate immune communication—such as targeting costimulatory pathways, cytokine signaling hubs, or metabolic checkpoints—hold promise for achieving broader and more sustained immunomodulation [12].

Therapeutic strategies informed by immune crosstalk principles are already reshaping clinical practice. Combination therapies that simultaneously affect multiple immune pathways reflect an implicit acknowledgment of network-based disease mechanisms. In neuroinflammatory diseases [13-16], treatments that stabilize the blood–brain barrier or modulate microglial activation demonstrate the value of targeting immune–tissue interactions. Future therapies may further refine this approach by selectively restoring regulatory crosstalk while dampening pathogenic communication circuits.

Importantly, immune crosstalk also influences disease heterogeneity and progression. Genetic predisposition, environmental exposures, and tissue-specific factors shape immune communication patterns, resulting in diverse clinical phenotypes even within the same diagnostic category. Understanding these individualized immune networks may enable personalized therapeutic strategies tailored to each patient's unique immunological landscape.

CONCLUSION

Immune crosstalk also influences disease heterogeneity and progression. Genetic predisposition, environmental exposures, and tissue-specific factors shape immune communication patterns, resulting in diverse clinical phenotypes even within the same diagnostic category. Understanding these individualized immune networks may enable personalized therapeutic strategies tailored to each patient's unique immunological landscape.

AUTHOR CONTRIBUTIONS

Conceptualization, literature synthesis, and manuscript preparation were performed by the authors.

CONFLICT OF INTEREST

The authors declares no conflict of interest.

FUNDING

No external funding was received for this work.

REFERENCES

1. Abbas, A. K., Lichtman, A. H., Pillai, S., Baker, D. L., and Baker, A. (2021). Cellular and molecular immunology. Elsevier, Philadelphia, PA.
2. Murphy, K., Weaver, C., and Janeway, C. (2022). Janeway's immunobiology. Garland Science, New York, NY.
3. Steinman, R. M., and Banchereau, J. (2007). Taking dendritic cells into medicine. Nature, 449(7161), 419–426.

4. Crotty, S. (2019). T follicular helper cell biology: A decade of discovery and diseases. Immunity, 50(5), 1132–1148.

5. Sakaguchi, S., Yamaguchi, T., Nomura, T., and Ono, M. (2008). Regulatory T cells and immune tolerance. Cell, 133(5), 775–787.

6. Chitnis, T., Weiner, H. L., and Khoury, S. J. (2008). The role of Th17 cells in the pathogenesis of autoimmune disease. Nature Reviews Immunology, 8(10), 845–858.

7. Prinz, M., Priller, J., Sisodia, S. S., and Ransohoff, R. M. (2011). Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nature Neuroscience, 14(10), 1227–1235.

8. Ransohoff, R. M., Brown, M. A., and Ramesh, G. (2015). Immune cell trafficking to the central nervous system. Nature Immunology, 16(5), 465–473.

9. McGeachy, M. J., Cua, D. J., and Gaffen, S. L. (2019). The IL-17 family of cytokines in health and disease. Immunity, 50(4), 892–906.

10. Wynn, T. A., Chawla, A., and Pollard, J. W. (2013). Macrophage biology in development, homeostasis and disease. Nature, 496(7446), 445–455.

11. Dendrou, C. A., Fugger, L., and Friese, M. A. (2015). Immunopathology of multiple sclerosis. Nature Reviews Immunology, 15(9), 545–558.

12. Smolen, J. S., Aletaha, D., and McInnes, I. B. (2016). Rheumatoid arthritis. Lancet, 388(10055), 2023–2038.

13. Bluestone, J. A., Bour-Jordan, H., Cheng, M., and Anderson, M. (2015). T cells in the control of organ-specific autoimmunity. Journal of Clinical Investigation, 125(6), 2250–2260.

14. Schwartz, M., and Baruch, K. (2014). The resolution of neuroinflammation in neurodegeneration. Nature Reviews Neurology, 10(4), 187–196.

15. Rothhammer, V., and Quintana, F. J. (2019). Control of autoimmune CNS inflammation by astrocytes. Seminars in Immunopathology, 41(6), 651–663.

16. Rao, D. A., Gurish, M. F., Marshall, J. L., Slowikowski, K., Fonseka, C. Y., Liu, Y., et al. (2017). Pathologically expanded peripheral helper T cell subset drives B cells in rheumatoid arthritis. Nature, 542(7639), 110–114.

Citation: Yang L, Yun W (2025) Immune Cell Crosstalk as a Central Mechanism in Autoimmune and Neuroinflammatory Disease. Appl Cell Biol, 13(3), [74-77]